Voyager Therapeutics Inc Stock
Price
Target price
€7.94
€7.94
1.710%
0.135
1.710%
€16.00
16.05.24 / Tradegate
WKN: A143XJ / Name: Voyager / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Voyager Therapeutics Inc Stock
Voyager Therapeutics Inc gained 1.710% today.
Our community is currently high on Voyager Therapeutics Inc with 3 Buy predictions and 0 Sell predictions.
Based on the current price of 7.94 € the target price of 16 € shows a potential of 101.51% for Voyager Therapeutics Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Voyager Therapeutics Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Voyager Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Voyager Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Voyager Therapeutics Inc | 1.710% | 1.211% | 9.593% | -34.918% | -0.126% | 119.945% | - |
| Ardelyx Inc. | -0.830% | -0.416% | 17.913% | 119.146% | 24.360% | 27.221% | - |
| Evolus Inc | 5.130% | 4.237% | 16.038% | 36.667% | 35.912% | 72.028% | - |
| Salarius Pharmaceuticals Inc. | 7.850% | -5.069% | -1.905% | -64.174% | -25.766% | -98.542% | -99.992% |
News
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with
